Cavion Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cavion inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cavion Inc Today - Breaking & Trending Today
gmmApril 25, 2021 This latest Childhood Absence Epilepsy Treatment report published by Global Market Monitor covers the current market dynamics, and provides effective competition strategies and market guidelines for the majority of practitioners. Childhood absence epilepsy (CAE), also known as pyknolepsy, is an idiopathic generalized epilepsy which occurs in otherwise normal children. The age of onset is between 4–10 years with peak age between 5–7 years. Children have absence seizures which although brief (~4–20 seconds), they occur frequently, sometimes in the hundreds per day. The absence seizures of CAE involve abrupt and severe impairment of consciousness. Mild automatisms are frequent, but major motor involvement early in the course excludes this diagnosis. The EEG demonstrates characteristic “typical 3Hz spike-wave” discharges. Prognosis is excellent in well-defined cases of CAE with most patients “growing out” of their epilepsy. ....
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results DUBLIN, Feb. 23, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2020 and provided financial guidance for 2021. In 2020, we made meaningful progress toward our goal to significantly grow and diversify 2022 revenues from products launched since 2019, highlighted by the strong execution of our U.S. launches of both Zepzelca and Xywav. Despite the pandemic, we delivered important new treatment options for patients, ensured the well-being of employees and generated significant value for shareholders. We meaningfully increased revenues, executed three product launches, advanced early- and late-stage clinical trials and added multiple new novel product candidates to our expanding pipeline, all of which exemplifies our highly effective operational execution throughout 2020, while continuing our transformation a ....